Drug Profile
Livoletide - Tempest Therapeutics
Alternative Names: AZP-531; UAG-analogue-Alize; Unacylated-analogue-AlizeLatest Information Update: 14 Apr 2022
Price :
$50
*
At a glance
- Originator Alize Pharma
- Developer Tempest Therapeutics
- Class Anti-ischaemics; Antihyperglycaemics; Cyclic peptides; Obesity therapies; Peptide hormones
- Mechanism of Action Ghrelin antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Ischaemia; Prader-Willi syndrome; Type 2 diabetes mellitus
Most Recent Events
- 06 Apr 2020 Discontinued - Phase-I for Type 2 diabetes mellitus in United Kingdom (SC) before April 2020
- 06 Apr 2020 Discontinued - Phase-II/III for Prader-Willi syndrome (In adolescents, In children, In the elderly, In adults) in France, Spain, Spain, USA, Australia, Belgium, Netherlands, United Kingdom, Italy (SC)
- 06 Apr 2020 Discontinued - Preclinical for Ischaemia in USA (unspecified route) before April 2020